Kornimate/medical-research-clean huggingface dataset:
management of lower pole renal hard stones ≤2 cm

Conditions: Renal Stones

Summary: the study has been conducted in urology department at kafrelsheikh university hospital between march 2022 to march 2023. informed consent was taken from eligible patients and were randomized into three groups, group a :flexible ureteroscope (f-urs) group underwent holmium laser lithotripsy using flexible ureteroscopy (boston® scientific (lithovue) while, group b : extracorporeal shock wave lithotripsy (eswl) group underwent electromagnetic extracorporeal shock wave lithotripsy (storz® medical modulith slx-f2 fd21, germany) .group c : mini perc group underwent holmium laser lithotripsy using karl® storz mip set.


Eligibility criteria:
inclusion criteria: * adult patient older than 18 years. * single renal stone. * medium sized stone up to 2.0 cm . * do novo * stone in lower calyceal stone * hard stone exclusion criteria: * • multiple renal stones * stone size \> 2 cm * age group \< 18 * solitary kidney * patients with bmi \> 40 kg/m2 * bleeding disorders * anatomical renal abnormalities * obstruction distal to the stone. * musculoskeletal deformities

Keywords: hard stones
evaluation of the performance of epidural analgesia after major abdominal surgery

Conditions: Epidural Analgesia After Major Open Abdominal Surgery

Summary: epidural analgesia is widely used for the treatment of acute postoperative pain, and currently represents the gold standard after open major abdominal surgery. however, several studies have reported a failure rate of apt of up to 30%. its efficacy regarding pain control during coughing and mobilization is also inconsistent, with correct analgesia found in only 60% of cases in a scandinavian multicenter cohort. inadequate epidural analgesia may be associated with more postoperative complications. this finding prompts a study in our institution to evaluate the performance of epidural analgesia after major open abdominal surgery.

epidural analgesia is widely used for the treatment of acute postoperative pain, and currently represents the gold standard after open major abdominal surgery. however, several studies have reported a failure rate of apt of up to 30%. its efficacy regarding pain control during coughing and mobilization is also inconsistent, with correct analgesia found in only 60% of cases in a scandinavian multicenter cohort. inadequate epidural analgesia may be associated with more postoperative complications. this finding prompts a study in our institution to evaluate the performance of epidural analgesia after major open abdominal surgery. epidural analgesia does not guarantee total control of acute postoperative pain after major open abdominal surgery. the performance of epidural analgesia could vary according to predisposing factors and postoperative days. inadequate epidural analgesia could be associated with greater morbidity after open major abdominal surgery. in order to evaluate the performance of epidural analgesia after major open abdominal surgery, a prospective observational monocentric scheme seems relevant. the evaluation will be clinical based on questioning and a brief medical examination during the early postoperative phase of the operated patients.

Eligibility criteria:
inclusion criteria: * major abdominal surgery patient operated by laparotomy (predicted operative time ≥ 2 hours) * epidural analgesia accepted exclusion criteria: * minor or protected patient * patients under guardianship, curatorship or safeguard of justice * pregnant or breastfeeding woman * contraindication or refusal of epidural analgesia * failure of the initial placement of the epidural catheter * major intraoperative complication requiring continued postoperative sedation

Keywords: epidural analgesia open abdominal surgery postoperative pain
lymphoedema and nocturia/ nocturnal polyuria after pelvic lymph node dissection for urogenital cancer

Conditions: Lower Limb Lymphedema; Urogenital Cancer

Summary: after the treatment of urogenital cancer, a person may develop lymphoedema of the leg(s) and/ or midline region. lymphoedema is the result of a dysfunction in the lymphatic system and is characterized by excessive retention of lymphatic fluid in the interstitial compartment, adipose deposition and chronic tissue inflammation resulting in fibrosis. clinical symptoms include abnormal tissue swelling, sensation of limb heaviness, erythema, pain, and impaired limb function. the added value of manual lymph drainage, applied in patients with mild (early) lower limb lymphoedema and in addition to skin care, exercises and a compression stocking, has never been investigated. therefore, the objective of this randomised controlled pilot trial is to investigate the feasibility of a trial about the added value of manual lymph drainage (to skin care, exercises and wearing compression stocking) in patients with mild (early) lower limb lymphoedema. in fact, the investigators want to determine the sample size for a trial investigating the effectiveness of mld and want to investigate the feasibility of the study design.


Eligibility criteria:
inclusion criteria: * patients included in the prospective observational study and developing lymphoedema within the first year after surgery * before inclusion, written informed consent must be given according to ich/gcp, and national/local regulations. inclusion criteria of the prospective observational study were: * non-metastatic urogenital cancer (i.e. prostate cancer or bladder cancer) * pelvic lymph node dissection exclusion criteria: same as for the prospective observational study: * radiological evidence of metastatic disease based on pelvic ct/mri and bone scan * clinical signs of chronic venous insufficiency

Keywords: manual lymph drainage
mentalizating in adults suffering from narcolepsy type 1.

Conditions: Narcolepsy Type 1

Summary: the main objective is to examine the potential mentalization impairments affecting a population suffering from narcolepsy type 1. indeed, the hypothesis of this research is that mentalization could be impaired in narcoleptic patients.

narcolepsy type 1 (nt1) is a rare and still poorly understood pathology which can have a significant impact on patient's daily life. beyond the experience of their chronic illness, their feelings about the difficulties they go through during their lives seem relatively blunted, as if what could be described as restrictive could be acceptable for them. moreover, the response generated by constraint, even if it is a refusal, rarely turns out to be impulsive or aggressive. rapid eye movement (rem) sleep is known to play a role in emotional regulation and also in narcolepsy. these processes both take place in hypothalamus, so, a link between them seems conceivable. surprisingly, the studies about depression, impulsivity, addictions, facial emotional recognition in narcoleptic patients show results that differs from the expectations of the investigators, and can even be at the opposite. it appears difficult to have a clear idea of the mental state of narcoleptic patients. mentalization is a concept with a strong empirical base. it corresponds to ability to understand the mental state, of oneself or others, that underlies overt behaviour. the idea of this research is that this process is modified in narcoleptic patients. the main objective is to examine the potential mentalization impairments affecting a population suffering from narcolepsy type 1. to realise this study a group of patients with nt1 and a control group will complete several questionnaires which are validated about mentalization and other ones. this combination of questionnaire is designed to evaluate the comparability of the groups and search for potential confounding factors.

Eligibility criteria:
inclusion criteria: for the nt1 patient group: * adult patient having been diagnosed with type 1 narcolepsy according to icsd 3 criteria and the completion of a 48-hour polysomnography at the sleep laboratory * patient affiliated to or beneficiary of a social security system for the control group: * patient over 18 years old * patient followed at toulouse university hospital and treated for obstructive sleep apnea (osa) with a residual ahi \<5/h, demonstrating the absence of residual osa under treatment * patient affiliated to or beneficiary of a social security system exclusion criteria: * patient with a history of autism spectrum disorder, chronic psychotic disorder, or bipolar disorder. * patient with a history of cognitive disorders of neurological origin * patient with a linguistic level in french that does not allow sufficient understanding to complete the questionnaires * patient under legal protection measure, under guardianship or curatorship * pregnant or breastfeeding woman

Keywords: narcolepsy type 1 mentalization reflective functioning questionnaire mental states task
oral propranolol for reducing pediatric dental patients anxiety

Conditions: Extrusion of Tooth

Summary: evaluating anxiety, heart rate and behavior during dental extractions after oral dose of either propranolol, midazolam or a combination of both in uncooperative pediatric patients.

use of 0.5 mg/kg of propranolol or a combination of propranolol and midazolam for the first time to manage uncooperative pediatric dental patients anxiety, comparing with midazolam by evaluating anxiety, heart rate and behavior during administration of local anesthesia and extraction.

Eligibility criteria:
inclusion criteria: * high to extreme fear of tooth or molar anesthesia and removal (frankl: definitely negative). * scoring more than 19 points on mcdas(f). * healthy pediatric patients (asa i) aging 8-10 years. * indication for primary tooth or molar extraction. * fasting if indicated (severe gag reflex). * airway assessment (mallampati and tonsillar hypertrophy). exclusion criteria: * asthma or any other obstructive pulmonary disease. * cardiac failure. * cardiac arrhythmia. * renal failure. * diabetes. * current use of another ß-adrenoreceptor antagonist. * current use of anxiolytic or antidepressant medication. * currently in psychotherapy for dental anxiety. * systolic blood pressure \<100 mmhg. * diastolic blood pressure \<60 mmhg. * active upper respiratory infection.
retrospective study on anosmias and ageusias linked to infection by covid-19

Conditions: Covid-19

Summary: odor and taste disturbances have increased dramatically during this time of the covid-19 pandemic. currently, we have very little information on the demographic and clinical characteristics of the affected population, on the severity and course of the olfactory / taste loss. the main objective of this research is to analyze the epidemiological, demographic and clinical characteristics of patients suspected or already confirmed of infection with sars-cov2 presenting with anosmia and / or ageusia.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * subject having had a loss of smell and / or taste that occurred during the period of the covid-19 epidemic with or without other symptom (s) suggestive of a covid infection -19 * subject with suspected or confirmed covid-19 infection * subject taken care of by the ent service * subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. exclusion criteria: * subject having expressed opposition to participating in the study * subject under guardianship or guardianship * subject under safeguard of justice

Keywords: covid-19 odor disturbance taste disturbances sars-cov2 anosmia ageusia
the effect of a supervised home-based tele-rehabilitation program on patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Telerehabilitation

Summary: tele-rehabilitation (tr) which carries health services distant through using electronic communication systems is an important treatment option. although tr studies in musculoskeletal system, neurologic and cardio-pulmonary diseases are effective tr studies in type 2 dm patients are limited. tr interventions in patients with type 2 diabetes has not yet sufficiently defined and more studies with different exercise protocols will be an important step for the clinical value of this intervention but also for it's application in clinical practice. objective: the aim of this study is to evaluate the effectiveness of a telerehabilitation program on glucose control, functional capacity, muscle strength and quality of life in patients with type 2 diabetes. study design: it is a supervised-double blind randomized controlled trial, comparing two groups (a control group and a telerehabilitation group). the duration of the intervention will last 6 weeks. setting: home-based patients environments , only the first session in university of thessaly for educational reason participants: a total of 22 patients with type 2 diabetes, regardless sex, aged 40 years and older will randomly assign to a telerehabilitation group (n = 11) and a control group (n = 11). measurements /assessments study data will be collected at baseline and after the intervention period ( 6 weeks) by two blinded physiotherapists, in university of thessaly).

procedure: the intervention program will last for 6 weeks and the patients in telerehabilitation-group will receive home based exercise program (by video-call with the supervision of a physiotherapist), 3 times per week and the total duration of each session will last for 60 minutes. the control group will not receive any exercise intervention during that period but only an educational session. clinical assessments wiil be conducted before and 6 weeks after intervention and will include: 1. functional capacity assesment tool : six minutes walking test ( 6mwt) 2. physical activity\] assesment tool : international physical activity questionnaire (ipaq). 3. quality of life assesment tool : 36-item short form survey (sf-36) sf36 4. hand grip strength assesment tool : jamar hydraulic hand dynamometer 5. leg strength and endurance assesment tool 30 second chair stand test 6. weight, hip , waist and bmi measurements 7. hba1c level assesment tool : blood test

Eligibility criteria:
inclusion criteria: * diabetes type 2 * regulated blood sugar * treatment by doctor * greek language exclusion criteria: * no internet connection * diabetes type 1 * recently surgery * mental health problems

Keywords: supervised exercise functional capacity hand grip
randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe combination for high-risk cardiovascular diseases (racing trial)

Conditions: Cardiovascular Diseases; Cerebrovascular Disease; Peripheral Atherosclerotic Disease

Summary: the clinical efficacy of ldl-lowering therapy have been proven with strong evidences and more emphasized. however, there are also growing concerns that high-intensity statin would be related to increased risk of adverse effects. in addition, there was an inconsistency of efficacy of statin according to ethnic population. asian population showed more profound ldl reduction not only from high potent statin but from moderate to low potent statin. conventional strategies for lowering ldl-cholesterol was focused on statins, therefore doubling of previously described dose of statin would be common way in patients with inadequate lowering ldl-cholesterol level. additive ezetimibe will also an alternative strategy not only to lower ldl-cholesterol level and also to reduce the need of dosage of high-intensity statin to fulfill sufficient ldl-cholesterol lowering effect. we will evaluate whether additive ezetimibe with rosuvastatin will have comparable clinical efficacy in terms of clinical outcomes and goal attainment of ldl-c compared to rosuvastatin monotherapy.


Eligibility criteria:
inclusion criteria: * age 19-80 years * documented cvd (cardiovascular disease), previous mi(myocardial infarction), acs (acute coronary syndrome), coronary revascularization and other arterial revascularization procedures, ischemic stroke, or pad (peripheral artery disease) exclusion criteria: * active liver disease or persistent unexplained serum ast or alt elevation more than 2 times the upper limit of normal range * allergy or hypersensitivity to any statin or ezetimibe * solid organ transplantation recipient * history of any adverse drug reaction requiring discontinuation of statin * pregnant women, women with potential childbearing, or lactating women * life expectancy less than 3 years * inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator * inability to understand or read the informed content
the efficacy of high density formula 1.5 kcal/ml or 1 kcal/ml on catch up growth in growth faltering children

Conditions: Growth Faltering; High Density Formula; Catch Up Growth

Summary: high density calorie is an oral nutrition supplement (ons) which is a high calorie formula (high density formula) and suggested as nutritional therapy to assist children who are undernourished or undergoing growth faltering. the world health organization (who) and the indonesian ministry of health have established regulations governing the use of ons for children suffering from undernutrition, whether or not an infection is present. ons available on the indonesian market provides an energy density of between 1-1.5 kcal/ml. this study has the potential to clarify the advantages of ons administration and evaluate its efficacy in comparison to nutritional therapy (1 kcal/ml or 1.5 kcal/ml) to facilitate rapid catch-up growth by examining the rate of increase in body weight, body lenght and undernourished children, particularly when infection is present. purposes: 1. analyze the effect of the 1.5 kcal/ml high dense formula (ons) on the average weight gain in undernourished children accompanied by infections 2. analyze the effect of the 1.5 kcal/ml calorie dense formula (ons) on the average increase in pb in undernourished children accompanied by infections 3. analyze the effect of the 1 kcal/ml calorie dense formula (ons) on the average weight gain in undernourished children accompanied by infections 4. analyze the effect of 1 kcal/ml calorie dense formula (ons) on the average increase in pb in undernourished children accompanied by infections 5. analyze the effect of the 1.5 kcal/ml calorie dense formula (ons) on changes in nutritional status in undernourished children accompanied by infections

this research is a retrospective observational study using medical record data from the emr husada utama hospital. based on the emr, data will be taken on patients who are able to consume 300-400 kcal of solid food, given 400 cc ons 1.5 kkal/ml (nutrini drink) equivalent to 600 kcal as group 1. patients who are able to consume 500-600 kcal solid food are given 1 kkal/ml 400 cc ons (sgm optigrow) equivalent 400 kcal as group 2. the rate of increase body weight and body height will be measured at day 0, 30 , 60 and 90 after consumed high dense formula, then it will be plotted in who growth chart to show the enhancement of nutrition status. the statistical analysis including test of normality and homogeneity test, followed by paired sample t-test or wilcoxon, depend on the normality and homogeneity test.

Eligibility criteria:
inclusion criteria: * children aged 1 years - 5 years, are diagnosed tuberculosis (tb) and urinary tract infection (uti) * children who have feeding difficulties * children who malnourished or have undergoing weight malnutrition exclusion criteria: * children with fluid retention * children with organomegaly * children with tumor masses. * children with congenital abnormalities * children wither cerebral palsy, hormonal disorders, and syndromes.

Keywords: growth failure growth faltering high density formula catch up growth
a pharmacodynamic study with ticagrelor in hispanic patients

Conditions: Stable Coronary Artery Disease

Summary: the purpose of this study is to assess the pharmacodynamic effect of ticagrelor in hispanic patients with stable coronary artery disease.

a randomized, open-label, multiple dose, crossover, multiple center study of the antiplatelet effects of ticagrelor versus clopidogrel in hispanic patients with stable coronary artery disease

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent before initiation of any study-related procedures * male or female patients aged 18 years or older documented stable cad fulfilling and taking 75-100mg asa daily treatment * females must be post menopausal or surgically sterile self-identified as hispanic exclusion criteria: * any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, asa dose other than 75 to 100 mg daily) during study period * patients who had acs or stent placed within 12 months of screening patients with a history of moderate or severe hepatic impairment * current smokers, including the use of tobacco containing products in the past 1 month of randomization * patients requiring dialysis

Keywords: stable coronary artery disease, cad
comparison between all immunotherapies for multiple sclerosis.

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: the overarching goal of this study is to determine whether rituximab (rtx) offers effectiveness and safety advantages over other commonly used approved disease-modifying drugs (dmt) in the largest real-world population-based structured prospective follow-up cohort of relapsing-remitting multiple sclerosis (rrms) patients. the study will include both treatment naïve patients starting their first dmt and patients switching from a previous first line dmt (escalation/second-line).

this is a prospective non-intervention observational prospective cohort study assessing the long-term safety and efficacy of rtx treatment in ms compared with other common ms dmts regarding both clinical and radiological parameters in a real-life population of patients with ms. a number of parameters will be assessed annually. these include baseline demographics, previous drug history and reasons for discontinuation, disability status (expanded disability status scale), relapses, safety and adverse events (ae), contrast enhancing t1 and newly appearing t2 lesions on magnetic resonance imaging, as well as a panel of patient reported outcome measures: symbol digit modalities test (sdmt); ms impact scale-29 (msis-29) fatigue scale for motor and cognitive functions (fsmc), euroqol-5 dimensions (eq-5d), the ms check scale and treatment satisfaction questionnaire 9 (tsqm-9). retrospective data entered in medical charts and the swedish ms registry will be included together with prospective annual structured follow up from inclusion into the study for a minimum of three years (three to nine years). in a substudy - covid enhancement study - analyses will be performed regarding the effect of covid-19 on people with ms as compared to non-ms individuals and also if there is any indication that a particular dmd is associated with a risk to contract a more severe covid-19. the analyses will primarily be performed in official health care databases.

Eligibility criteria:
inclusion criteria: the study population consists of all patients with clinically isolated syndrome (cis) or rrms who; * initiate a first ms dmt (treatment naïve), or initiate a second ever dmt, of a different drug class than the first, regardless of time between drugs or reason for discontinuation("switchers") from 1st jan 2011 to 30st june 2018, and * are followed at any of the university clinics of sweden, and * consent to participation in combat-ms core, and * are expected to be capable to follow study assessments. exclusion criteria: - patients with progressive forms of ms at start of therapy are not eligible

Keywords: immunomodulating treatment cohort study dimethyl fumarate fingolimod interferon-beta natalizumab rituximab glatiramer acetate